Altavant Sciences is a clinical stage biopharmaceutical company formed to advance promising therapies that treat rare respiratory diseases with an initial therapeutic focus in pulmonary arterial hypertension. Altavant's lead investigational candidate is rodatristat ethyl, a pro-drug of a tryptophan hydroxylase (TPH) inhibitor, designed to block peripheral serotonin production. Rodatristat ethyl is being evaluated to treat PAH and Altavant is exploring if rodatristat ethyl halts or reverses pulmonary vascular remodeling caused by increased serotonin production in pulmonary artery cells. ELEVATE 2 (NCT04712669) is a Phase 2b, double-blind, multicenter trial where patients with PAH are randomized to placebo, 300 or 600 mg twice daily of rodatristat ethyl. The trial incorporates endpoints to generate clinical efficacy, safety, pharmacokinetic, and pharmacodynamic data needed to evaluate the potential ability of rodatristat ethyl to provide therapeutic benefit through its unique mechanism of TPH inhibition.